A Pharmaceutical Executive on Trump’s Tariff Strategy
Jul 28, 2025•17 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Earlier this month, President Donald Trump announced the U.S. would impose up to a 200% tariff on imported pharmaceuticals, though he would give them up to a year and a half before fully implementing the tariffs. Trump’s goal is to bring more manufacturing to the United States, but one pharmaceutical CEO, Richard Saynor of Sandoz, says there is little incentive to build in the U.S. Jessica Mendoza hosts.
Further Listening:
- Why Trump Pushed His Tariff Deadline
- Inside the Surprise U.S.-China Trade Deal
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
For the best experience, listen in Metacast app for iOS or Android